Abstract
Recombinant activated factor VII, (rFVIIa, NovoSeven®, Novo Nordisk), is licensed in the UK, Europe and US for treatment of haemophilia patients with inhibitors to factors VII and IX, during bleeding episodes occurring spontaneously or caused by trauma or surgery. It has been approved for use in patients with factor VII deficiency and Glanzmann’s thrombasthenia. [1] O’Connell Wood J.J. Wise R.P. et al. Thromboembolic adverse effects after use of recombinant human coagulation factor VIIa. JAMA. 2006; 295: 293-298 Crossref PubMed Scopus (575) Google Scholar It is not licensed for use in any other group of patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
